

Demuth et al.
U.S.S.N.: 09/682,968
Page 2 of 9

In the claims:

Please cancel claims 6-11 without prejudice.

1. (PREVIOUSLY AMENDED) A method of raising the blood sugar level in a mammal having hypoglycemia by reducing degradation of glucagon, said method comprising administering to said mammal a therapeutically effective amount of an effector ^{or} for reducing enzymatic activity of dipeptidyl peptidase (DP IV) and DP IV analogous enzymes.

and/or excipients which raise the blood sugar level in a mammal having hypoglycemia
2. (ORIGINAL) The method of claim 1, wherein the blood sugar level in the serum of mammalian organisms is raised above the glucose concentration characteristic of hypoglycemia.

3. (PREVIOUSLY AMENDED) The method of claim 1, wherein the effector is selected from the group consisting of DP IV ~~enzyme~~ inhibitors, substrates of DP IV, pseudo-substrates of DP IV, inhibitors of DP IV expression, proteins that bind DP IV or antibodies to DP IV and combinations thereof.

4. (PREVIOUSLY AMENDED) The method of claim 1, wherein the effector for reducing enzymatic activity is employed together with glucagon or analogues thereof.

5. (PREVIOUSLY AMENDED) The method of claim 1, wherein the effector for reducing enzymatic activity is employed in combination with physiologically acceptable adjuvants and/or excipients.

6. (CANCELLED) A method of raising the blood sugar level in a mammal having hypoglycemia by ~~A method for~~ stimulating endogenous glucose production via glucagon stabilization in a mammal comprising the step of administering to said mammal a therapeutically effective amount of Dipeptidyl peptidase IV inhibitor in a pharmaceutically acceptable preparation for reducing in said mammal the enzymatic activity of endogenous DP IV and thereby reducing degradation of glucagon.

Demuth et al.
U.S.S.N.: 09/682,968
Page 3 of 9

7. (CANCELLED) A method of raising the blood sugar level in a mammal having hypoglycemia by reducing degradation of glucagon, said method comprising administering to said mammal a therapeutically effective amount of a compound having a means for ~~modulating~~ influencing enzymatic activity of dipeptidyl peptidase (DP IV) and DP IV-analogous enzymes.

8. (CANCELLED) The method of claim 7, wherein the blood sugar level in the serum of mammalian organism is raised above the glucose concentration characteristic of hypoglycemia.

9. (CANCELLED) The method of claim 1, wherein said compound is selected from the group consisting of DP IV enzyme inhibitors, substrates of DP IV, pseudo-substrates of DP IV, inhibitors of DP IV expression, proteins that bind DP IV or antibodies to DP IV and combinations thereof.

10. (CANCELLED) The method of claim 7, wherein said means for ~~modulating~~ influencing enzymatic activity is employed together with glucagon or analogues thereof.

11. (CANCELLED) The method of claim 7, wherein said means for ~~modulating~~ influencing enzymatic activity is employed in combination with physiologically acceptable adjuvants and/or excipients.